$31.26
0.22% yesterday
Nasdaq, Feb 04, 10:00 pm CET
ISIN
GB00BMVP7Y09
Symbol
RPRX
Sector
Industry

Royalty Pharma plc - Ordinary Shares - Class A Stock price

$31.26
+5.51 21.40% 1M
+3.80 13.84% 6M
+5.75 22.54% YTD
+3.55 12.81% 1Y
-8.71 21.79% 3Y
-13.24 29.75% 5Y
-13.24 29.75% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.07 0.22%
ISIN
GB00BMVP7Y09
Symbol
RPRX
Sector
Industry

Key metrics

Market capitalization $13.89b
Enterprise Value $23.89b
P/E (TTM) P/E ratio 12.23
EV/FCF (TTM) EV/FCF 8.46
EV/Sales (TTM) EV/Sales 10.54
P/S ratio (TTM) P/S ratio 6.13
P/B ratio (TTM) P/B ratio 2.03
Dividend yield 2.69%
Last dividend (FY24) $0.84
Revenue growth (TTM) Revenue growth -2.52%
Revenue (TTM) Revenue $2.27b
EBIT (operating result TTM) EBIT $1.54b
Free Cash Flow (TTM) Free Cash Flow $2.82b
Cash position $998.55m
EPS (TTM) EPS $2.56
P/E forward 19.91
P/S forward 5.17
EV/Sales forward 8.88
Short interest 3.89%
Show more

Is Royalty Pharma plc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Royalty Pharma plc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

Buy
78%
Hold
22%

Financial data from Royalty Pharma plc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,266 2,266
3% 3%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 720 720
41% 41%
32%
- Research and Development Expense 2.50 2.50
98% 98%
0%
1,544 1,544
53% 53%
68%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,544 1,544
53% 53%
68%
Net Profit 1,146 1,146
521% 521%
51%

In millions USD.

Don't miss a Thing! We will send you all news about Royalty Pharma plc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Royalty Pharma plc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
7 days ago
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with payments previously received, results in total cash proceeds of $530 million on the $300 million investment that was made in Sep...
Neutral
GlobeNewsWire
8 days ago
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day.
Positive
Seeking Alpha
21 days ago
Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savi...
More Royalty Pharma plc - Ordinary Shares - Class A News

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.

Head office United Kingdom
CEO Pablo Legorreta
Employees 89
Founded 1996
Website royaltypharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today